Business
Cardiol Therapeutics Reports Results of 2021 Annual General and Special Meeting
Oakville, Ontario--(Newsfile Corp. - June 30, 2021) - Cardiol Therapeutics Inc. ( TSX: CRDL ...
About this update from Cardiol Therapeutics Inc. Class A
[{"type":"text","content":"Cardiol Therapeutics Reports Results of 2021 Annual General and Special MeetingOakville, Ontario--(Newsfile Corp. - June 30, 2021) - Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) (FSE: CT9) (\"Cardiol\" or the \"Company\"), a clinical-stage biotechnology company focused on developing innovative anti-inflammatory therapies for the treatment of cardiovascular disease, announces results from its Annual General and Special Meeting of Shareholders (the \"AGM\") held virtually via live audio webcast, on June 29, 2021. Shareholders voted in favour of all management resolutions proposed in the Company's Information Circular.Resolutions proposed and approved at the AGM were:The re-election of the following directors for the ensuing year: David Elsley, Dr. Eldon R. Smith, Deborah Brown, Iain Chalmers, Peter Pekos, Dr. Guillermo Torre-Amione, Colin StottThe appointment of BDO Canada LLP as auditors of the Company until the next annual meeting and the authorization of the directors of the Company to fix the remuneration to be paid to the auditorsThe approval of the Company's Omnibus Equity Incentive PlanThe results of the voting on the election of directors are as follows: NomineesNumber of Shares ForPercentage of Votes CastDavid Elsley16,763,47993.00%Dr. Eldon R. Smith16,763,17993.00%Deborah Brown17,994,68699.83%Iain Chalmers16,414,12991.06%Peter Pekos16,411,07991.05%Dr. Guillermo Torre-Amione18,000,88699.87%Colin Stott18,001,86199.87% About Cardiol TherapeuticsCardiol Therapeutics Inc. (TSX: CRDL) is a clinical-stage biotechnology company focused on the research and clinical development of innovative anti-inflammatory therapies for the treatment of cardiovascular disease (\"CVD\"). The Company's lead product, CardiolRx™, is a pharmaceutically produced oral cannabidiol formulation that is being investigated in a Phase II/III outcomes study in hospitalized patients testing positive for the COVID-19 virus. This potentially registrational trial is designed to evaluate the efficacy and safety of CardiolRx as a cardioprotective therapy to reduce mortality and major cardiovascular events in COVID-19 patients who have a prior history of, or risk factors for, CVD, and to investigate the influence CardiolRx has on key markers of inflammatory heart disease.Cardiol is also planning to file an investigational new drug (\"IND\") appl...